Clinuvel Pharmaceuticals (CUV) Fundamentals 2026 — P/E 15.2x, Revenue Analysis | SniperIQ
Clinuvel Pharmaceuticals (CUV) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A$498M, trading at A$9.88 on the ASX. This SniperIQ fundamentals page covers Clinuvel Pharmaceuticals's valuation (P/E 15.2x, P/B 2.0x), profitability (net margin 33.8%), revenue (A$95M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Clinuvel Pharmaceuticals's market cap?
Clinuvel Pharmaceuticals (CUV) has a market capitalization of approximately A$498M, trading at A$9.88 on the ASX. Market cap moves with the live share price.
What is Clinuvel Pharmaceuticals's P/E ratio?
Clinuvel Pharmaceuticals's trailing twelve-month P/E ratio is 15.2x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Clinuvel Pharmaceuticals?
Clinuvel Pharmaceuticals runs a net profit margin of 33.8%, a gross margin of 63.7%, and an operating margin of 39.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Clinuvel Pharmaceuticals generate?
Clinuvel Pharmaceuticals reported revenue of A$95M for fiscal year 2025, with net income of A